AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00394329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
Study NCT00394329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
Study NCT00394329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate
Description: Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
Study NCT00394329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate
Description: Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
Study NCT00394329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol sulfate
Description: Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
Study NCT00921427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: 2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
Study NCT03343782 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Expanded autologous bone marrow-derived mesenchymal stem cell
Description: Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
Study NCT00391807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate/ethinyl estradiol
Description: one tablet per day
Study NCT02151968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anaesthetic Injection
Description: Local anaesthetic is injected into the eye.
Study NCT02151968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anaesthetic Injection
Description: Local anaesthetic is injected into the eye.
Study NCT02151968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guidance
Description: Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance.
Study NCT04458363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma (CP)
Description: Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria), an ABO compatible product will be identified. The CP dose administered will be 10mL/kg/dose (up to 2 units per dose) times two doses per patient for a total dose of 20 mL/kg. Patients will be followed for adverse events and clinical response. Research blood testing will be obtained prior to infusion (baseline) and serially weekly afterwards until clinical resolution. Patients will receive 2 doses equaling 20 mL/kg (if available) of ABO compatible CP over 24-48 hours if they do not experience grade 3-5 adverse events that are possible, probably, or definitely attributed to CP after the first dose. Patients will be followed for adverse events for a minimum of 28 days after the last infusion of CP.
Study NCT04458363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard COVID-19 therapies
Description: If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
Study NCT02678728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
Study NCT02678728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
Study NCT00047008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 100 mg/m\^2 intravenously on days 1, 22
Study NCT00047008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: 100 mg/m\^2 intravenously on days 1, 22
Study NCT00047008 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Standard fractionation RT
Description: Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
Study NCT01671553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling group
Description: The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
Study NCT00402324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
Study NCT00402324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, capsules, by mouth every evening, daily, for 6 weeks.
Study NCT00402324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex
Description: dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
Study NCT00402324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: divalproex
Description: dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
Study NCT02412189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintained blood pressure
Description: Norepinephrine therapy to maintain preanesthesia blood pressure
Study NCT03909841 — intervention group
Intervention type: OTHER
Intervention: Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
Description: Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
Study NCT04496271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIC (Receiver in channel)- device
Description: HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
Study NCT04496271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC (Receiver in channel)- device
Description: HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
Study NCT02124083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Histone deactylase inhibitor
Study NCT01277991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
Study NCT01277991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
Study NCT02412189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine therapy to maintain preanesthesia blood pressure
Study NCT01670279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: up to 3mg oral dose once daily
Study NCT01670279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00847379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
Study NCT02672865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
Study NCT01433705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rb-82 Pet scans
Description: Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
Study NCT01433705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: F-18 FDG Pet scans
Description: Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol.
Study NCT01433705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: N-13 ammonia Pet scans
Description: Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
Study NCT01433705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regadenoson
Description: Regadenoson is used as a stressor; but not to study its effects.
Study NCT04224441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine Pill
Description: The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
Study NCT02794896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose propofol, fentanyl and sevoflurane
Description: Deep Anesthesia
Study NCT02794896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose propofol, fentanyl and sevoflurane
Description: Shallow Anesthesia
Study NCT00513084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDT and Motivational Interviewing in Obesity Treatment
Description: Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
Study NCT03954886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plus powered optical lens
Description: A plus powered optical lens will be placed in front of one eye.
Study NCT06040684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Level of antibodies
Description: The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
Study NCT03205358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular (IM)
Study NCT03205358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
Description: 0.5 mL, IM
Study NCT00047008 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiation therapy
Description: Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
Study NCT00047008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery for select patients
Description: Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made.
Study NCT00047008 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional surgery for select patients
Description: Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made.
Study NCT02884271 — intervention group
Intervention type: PROCEDURE
Intervention: cardiopulmonary resuscitation
Description: start cardiopulmonary resuscitation
Study NCT01660230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water
Study NCT01607463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (Empi, USA)
Description: In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
Study NCT01607463 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (Empi, USA)
Description: In the placebo group the TENS device had no current output although the power on indicator light remained active.
Study NCT03715140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crucumin
Description: Evaluation of the effect of Crucumin in patients with osteoarthritis
Study NCT03715140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02078024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM plus ALB
Study NCT02078024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVM
Study NCT02078024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM
Study NCT00637624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
Study NCT00637624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once every 3 weeks intravenous saline fluid
Study NCT00956722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum Powder
Description: Bovine Colostrum Powder (Biogard)
Study NCT00562822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgery
Description: Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
Study NCT00562822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical and medical therapy
Description: Treatment with physical and medical therapy alone
Study NCT03910790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 19 gauge needle liver biopsy
Description: Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
Study NCT04414813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Epithelial Stem Cells
Description: Stereotactic transplantation of hAESCs for participants with PD.
Study NCT03167190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Description: A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
Study NCT03167190 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional Landmark-based Lumbar Puncture
Description: Palpation of anatomical landmarks to identify midline and interspinous space
Study NCT01695590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRLX 93936
Description: PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
Study NCT05094583 — intervention group
Intervention type: BEHAVIORAL
Intervention: Use of SmokeFree app
Description: Intervention Arm
Study NCT03391037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Internal Jugular Vein Distensibility
Description: . 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
Study NCT02969369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 (25, 50, or 75mg/day)
Study NCT02969369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo once daily
Study NCT03885258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin Replacement Therapy
Description: Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
Study NCT03981770 — intervention group
Intervention type: DRUG
Intervention: General anesthesia
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
Study NCT03385460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWL BOTOX
Description: ESWL after intrravesical BOTOX
Study NCT01322269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1001
Description: HQK-1001 tablets, once daily for daily 26 weeks
Study NCT01571804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
Study NCT01571804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: two capsules of pregabalin 150 mg 1 hr before surgery
Study NCT02638337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene
Description: 60 mg tablet
Study NCT02638337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet identical to the ospemifene tablet without drug
Study NCT03578198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + MG4101
Description: 1. Induction phase:~   * Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~  * MG4101 3x107 cells/kg IV Weekly (X4)~2. Maintenance phase~   * Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~  * MG4101 3x107 cells/kg IV q 4 weeks (X4)
Study NCT03710798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate high fat diet
Description: Energy balanced low carbohydrate high fat diet during 6 weeks. Then 6-week reintroduction of a healthy normal diet